NASDAQ: CYPHCypherpunk Technologies Inc Stock
$0.64+0.03 (+4.92%)
Updated Jul 1, 2026
CYPH Price
$0.64
Fair Value Price
$0.20
Market Cap
$68.56M
52 Week Low
$0.23
52 Week High
$3.70
P/E
-32.2x
P/B
0.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$56.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$33M
Beta
1.72
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CYPH Overview
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CYPH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CYPH
Ranked#194 of 465
Ranked#194 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $237.51 | A | |
| $11.00 | A | |
| $15.80 | A |
Be the first to know about important CYPH news, forecast changes, insider trades & much more!
CYPH News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CYPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CYPH ($0.64) is overvalued by 225.16% relative to our estimate of its Fair Value price of $0.20 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CYPH ($0.64) is not significantly undervalued (225.16%) relative to our estimate of its Fair Value price of $0.20 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CYPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CYPH due diligence checks available for Premium users.
Valuation
CYPH fair value
Fair Value of CYPH stock based on Discounted Cash Flow (DCF)
Price
$0.64
Fair Value
$0.20
Overvalued by
223.14%
CYPH ($0.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CYPH ($0.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CYPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CYPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-32.2x
Industry
17.58x
Market
8.54x
CYPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.81x
Industry
5.43x
CYPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CYPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$77.2M
Profit Margin
0%
CYPH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$87.4M
Liabilities
$3.0M
Debt to equity
0.04
CYPH's short-term assets ($81.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYPH's short-term assets ($81.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$9.0M
Financing
$5.1M
CYPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CYPH vs Biotech Stocks
Cypherpunk Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.